

Genesis Oncology Trust

Financial Statements

For the Year Ended 30 June 2013

Contents

Trust Directory	1
Statement of Financial Performance	2
Statement of Movement in Equity	3
Statement of Financial Position	4
Notes to the Financial Statements	5
Audit Report	10

Genesis Oncology Trust

Trust Directory

For the Year Ended 30 June 2013

DATE OF DEED :

17 May 2002

REGISTERED OFFICE :

Level 1
Genesis Building
P O Box 17188
660 Great South Road
Greenlane
AUCKLAND
New Zealand

TRUSTEES :

Albert George Brantley
Maureen Grant Shaddick
Elizabeth Ann Marshall
Ann Kathleen Richardson
Robert Arthur Jay
Michael Barrett Jameson

TRUSTS CHARITABLE PURPOSE :

- a) to promote research in NZ into the detection, diagnosis and treatment of all forms of cancer and to provide associated training for health professionals;
- b) to promote the provision of palliative care;
- c) to assist hospitals, and associated health care providers with the provision of facilities in relation to oncology;
- d) to promote such other charitable purposes as the trustees may decide.

BANKERS :

Westpac
627 Great South Road
MANUKAU

SOLICITORS :

Taylor Grant Tesiram
P O Box 4039
AUCKLAND

AUDITORS:

Deloitte
P O Box 17
HAMILTON

Genesis Oncology Trust

Statement of Financial Performance

For the Year Ended 30 June 2013

	NOTE	2013 \$	2012 \$
REVENUE			
Interest Received-Current Account		14,990	20,098
Interest Received-Bonds		571,943	387,342
Distribution Shares		8,208	54,379
Interest Received – Shares Rebates		3,012	23,524
Interest Received – Term Deposit		4,992	21,116
Interest Received-ANZ WRAP Account		31,179	28,735
Interest Received-NZD WRAP Account		4,675	7,410
Interest Received-AUD WRAP Account		1,373	960
Interest Received-GBP WRAP Account		1	132
	2	<u>640,373</u>	<u>543,696</u>
Sponsorship Received – Genesis Energy Limited	3	200,000	200,000
Trust Expenditure Reimbursed	4	64,415	246,708
Donations Received – General		1,122,545	1,082,291
Unrealised Gain-Current Account		876	10,998
Unrealised Gain-Investment Shares		1,023,896	295,169
TOTAL REVENUE		<u>3,052,105</u>	<u>2,378,862</u>
OPERATING EXPENSES			
Advertising		-	1,000
Audit Fees		7,500	7,500
Bank Transaction Charges		224	272
Fees-Premium Plus Service		63,639	54,947
Consultants		64,925	62,671
General Expenses – Honorarium		21,470	20,845
Printing		64,363	236,476
Realised Loss Current Account		-	1,443
Unrealised Loss Current Account		947	6,621
Unrealised Loss-Investment Shares		63,587	521,258
		<u>286,655</u>	<u>913,033</u>
GRANTS			
Adjustments to Grants Allocated		(22,259)	(301,711)
Grants Allocated		1,445,099	1,152,034
TOTAL EXPENSES		<u>1,709,495</u>	<u>1,763,356</u>
RESIDUAL INCOME CURRENT YEAR		<u><u>1,342,610</u></u>	<u><u>615,506</u></u>

Genesis Oncology Trust

Statement of Movements in Equity

For the Year Ended 30 June 2013

	2013 \$	2012 \$
Opening Equity	11,963,124	11,347,618
Residual Income Current Year	1,342,610	615,506
<u>CLOSING EQUITY</u>	<u>13,305,734</u>	<u>11,963,124</u>



Genesis Oncology Trust

Statement of Financial Position

For the Year Ended 30 June 2013

	NOTE	2013 \$	2012 \$
TOTAL EQUITY		13,305,734	11,963,124
REPRESENTED BY:			
CURRENT ASSETS			
Westpac Current Account		164,205	85,661
Term Deposit		988,000	-
Westpac Short Term Deposit Account		1,004	705,963
Westpac Wrap Cash NZD Account		264,999	35,802
Westpac Wrap Cash AUD Account	7	21,742	153,017
ANZ Wrap Cash Account		391,712	360,532
Accounts Receivable – Invoice	6	314,859	314,529
GST Refunds Due		-	9,444
TOTAL CURRENT ASSETS		2,146,521	1,664,948
NON-CURRENT ASSETS			
Accrued Interest – Term Deposit		6,605	
Investments-Bonds	5	6,884,280	6,128,204
Investments-Shares	5	6,034,625	5,390,810
TOTAL NON-CURRENT ASSETS		12,925,510	11,519,014
TOTAL ASSETS		15,072,031	13,183,962
CURRENT LIABILITIES			
Accounts Payable		7,500	7,505
GST Payable		10,036	-
TOTAL CURRENT LIABILITIES		17,536	7,505
TERM LIABILITIES			
Provision for Grants		1,748,761	1,213,333
TOTAL LIABILITIES		1,766,297	1,220,838
NET ASSETS		13,305,734	11,963,124

Trustee:

Maureen Staddock
MAUREEN STADDOCK

Dated: 9 December 2013

for and on behalf of the Board of Trustees

Trustee:

Albert Brantley
Albert Brantley

Dated: 9 December 2013

"The above statements should be read in conjunction with the accompanying notes"



Genesis Oncology Trust

For the Year Ended 30 June 2013

1 STATEMENT OF ACCOUNTING POLICIES

These Financial Statements are presented in accordance with Generally Accepted Accounting Practice.

A GENERAL ACCOUNTING POLICIES

The general accounting policies recognised as appropriate for the measurement and reporting of results, and financial position, under the historical cost method have been followed in the preparation of these financial statements.

The Trust promotes the charitable purpose of cancer research and provides assistance to cancer health care providers.

B PARTICULAR ACCOUNTING POLICIES

The following particular accounting policies, which significantly affect the measurement of residual income and financial position, have been applied.

Differential Reporting

The Trust qualifies for differential reporting because it is not large and is not publicly accountable.

The Trust has taken advantage of all differential reporting exemptions with the exception of FRS 19 Accounting for GST.

These financial statements are not prepared under NZ equivalents to International Financial Reporting Standards (NZ IFRS) as the NZ Accounting Standards Board gave a temporary exemption from mandatory conversion for small organisations which fit the criteria for differential reporting.

Income Tax

The Trust has charitable status under the Income Tax Act and is exempt from income tax.

Accounts Receivable

Accounts receivable are stated at estimated realisable value. Amounts not considered recoverable are written off when identified as such.

Genesis Oncology Trust

For the Year Ended 30 June 2013

Investments

The Trust's investment funds have been placed in Westpac's PremiumPlus Service Portfolio in the form of investment bonds and investment shares.

Investment bonds are recorded at cost. Any premium or discount to maturity value is recognised as an interest expense/income over the remaining period to maturity.

Investment income is accounted for on an accrual basis.

Investment shares are initially recorded at cost and subsequently adjusted to fair value. Any fair value adjustments are treated as unrealised gains/losses in the statement of financial performance.

Distributions are recognised as they are received.

Grants & Distributions

Grants are included in the Statement of Financial Performance when approved by Trustees.

Donations Received

Donations are recognised on a cash receipts basis, with the exception of the monthly donations from Genesis Energy customer accounts. This is accrued at year end.

Sponsorship Received

Sponsorship funding is recognised on an accruals basis as per sponsorship agreements.

Goods and Services Tax

All revenue and expense transactions are recorded net of GST. Where applicable, all assets and liabilities have been stated net of GST with the exception of receivables and payables which are stated inclusive of GST.

Genesis Oncology Trust

For the Year Ended 30 June 2013

Foreign Currencies

Foreign currency transactions are recorded at the exchange rates in effect at the date of the transaction.

Financial Instruments

All financial instruments are recognised in the Statement of Financial Position. The Trust has not entered into any off-balance sheet instruments. The fair value of the financial instruments represents the carrying value of these items as recorded in the financial statements. The maximum exposure to credit risk is represented by the carrying value of each financial asset in the Statement of Financial Position.

C CHANGES IN ACCOUNTING POLICIES

There have been no changes to accounting policies throughout the year.

Genesis Oncology Trust

For the Year Ended 30 June 2013

	2013	2012
	\$	\$
2 INTEREST RECEIVED		
Westpac Current Account	14,990	20,098
WRAP Cash Accounts	37,228	37,237
Westpac Investment Accounts	4,992	21,116
Investment Portfolio	583,163	465,245
	<u>640,373</u>	<u>543,696</u>

The Westpac current account interest rate has ranged between 2.07% – 2.11% (2012: 1.98% – 2.16%).

Investment portfolio coupon interest rates ranged from 3.3% - 8.5% (2012: 3.7% - 8.5%).

3 SPONSORSHIP REVENUE

As per the Genesis Energy Limited sponsorship agreement with the Trust the annual amount of sponsorship for the year ended 30 June 2013 was \$200,000 (2012: \$200,000).

4 RELATED PARTIES

In addition to the sponsorship transaction above, Genesis Energy Limited facilitates its customers making donations via their monthly energy accounts. The receivable from Genesis Energy Limited is disclosed in Note 6.

Genesis Energy Limited paid expenses incurred by the Trust for the year ended 30 June 2013 of \$64,415 (2012: \$246,708).

Genesis Energy Limited provides the Trust with accounting and administrative support free of charge.

Albert Brantley is the Chief Executive of Genesis Energy Limited and the Chairman of the Trust. Maureen Shaddick is the General Counsel and Company Secretary of Genesis Energy Limited and is the Deputy Chair of the Trust.

As part of the investment portfolio, the Trust holds \$308,910 (2012: \$328,640) of Genesis Energy Limited Capital Bonds. The loss on the Genesis Energy Limited Capital Bonds recorded in the Statement of Financial Performance for the year ended 30 June 2013 was \$19,730 (2012: \$18,020 gain).

Genesis Oncology Trust

For the Year Ended 30 June 2013

5 INVESTMENTS

All of the investments held by the Trust are publicly traded bonds and shares. The total carrying value is \$12,918,905 (2012: \$11,519,014), with a face value of \$12,918,905 (2012: \$11,519,014). The maturity date of the bonds extends to July 2041 (2012: May 2041). The coupon rates range from 3.3% to 8.5% (2012: 3.7% to 8.5%).

	2013	2012
	\$	\$

6 ACCOUNTS RECEIVABLE

Related Party Receivables

Donations Receivable from Genesis Energy Limited	84,859	84,529
Customers	230,000	230,000
Genesis Energy Limited Sponsorship		
	<u>314,859</u>	<u>314,529</u>

7 FOREIGN CURRENCIES

As at 30 June 2013 the Trust had AUD \$18,265 (NZD equivalent \$21,742) in its Westpac Wrap AUD Cash Account (2012: AUD \$120,011, NZD equivalent \$153,017).

8 EVENTS OCCURRING AFTER BALANCE DATE

Effective 9 September 2013, the major sponsor of Genesis Oncology Trust changed its legal name from "Genesis Power Limited" to "Genesis Energy Limited".

INDEPENDENT AUDITOR'S REPORT TO THE TRUSTEES OF GENESIS ONCOLOGY TRUST

Report on the Financial Statements

We have audited the financial statements of Genesis Oncology Trust on pages 2 to 9, which comprise the statement of financial position as at 30 June 2013, and statement of financial performance and statement of movement in equity for the year then ended, and a summary of significant accounting policies and other explanatory information.

This report is made solely to the Trustees, as a body, in accordance with Section 8.7 of the Trust Deed. Our audit has been undertaken so that we might state to the Trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Trustees, as a body, for our audit work, for this report, or for the opinions we have formed.

Trustees' Responsibility for the Financial Statements

The Trustees are responsible for the preparation and fair presentation of financial statements, in accordance with generally accepted accounting practice in New Zealand, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibilities

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with International Standards on Auditing and International Standards on Auditing (New Zealand). Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of accounting estimates, as well as the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Other than in our capacity as auditor, we have no relationship with or interests in Genesis Oncology Trust.

Opinion

In our opinion, the financial statements on pages 2 to 9 present fairly, in all material respects, the financial position of Genesis Oncology Trust as at 30 June 2013, and its financial performance for the year ended on that date in accordance with generally accepted accounting practice in New Zealand.



Chartered Accountants
9 December 2013
Hamilton, New Zealand